Biosimilar SB17 versus reference ustekinumab in moderate to severe plaque psoriasis after switching: phase 3 study results up to week 52

Autor: Steven R. Feldman, Joanna Narbutt, Giampiero Girolomoni, Jan Brzezicki, Nataliya Reznichenko, Maria Agnieszka Zegadło-Mylik, Grazyna Pulka, Magdalena Dmowska-Stecewicz, Elżbieta Kłujszo, Dmytro Rekalov, Lidia Rajzer, Jiyoon Lee, Minkyung Lee, Young Hee Rho

Publikováno v: Journal of Dermatological Treatment, Vol 35, Iss 1 (2024)

Introduction SB17 is a biosimilar to reference ustekinumab (UST). We compared the efficacy, safety, and immunogenicity of SB17 to UST up to Week 52, including switching from UST to SB17.Methods Subjects were randomized to receive 45 mg of SB17 or UST

Externí odkaz: https://doaj.org/article/6c23eae0b2e24e7484f961e0f4edf041

Safety and Tolerability of Bilastine 0.6% Ophthalmic Solution: An 8-Weeks Phase III Study

Autor: Piotr Kuna, Marek Jutel, Grazyna Pulka, Slawomir Tokarski, Paula Arranz, Gonzalo Hernández, Nieves Fernández Hernando

Publikováno v: Clinical Ophthalmology.

Piotr Kuna,1 Marek Jutel,2,3 Grazyna Pulka,4 Slawomir Tokarski,5 Paula Arranz,6 Gonzalo Hernández,6 Nieves Fernández Hernando6 1Department of Internal Medicine, Asthma and Allergy, Medical University of Lodz, Lodz, Poland; 2Department of Clinic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f337975594a0a254a8008d6a480e712
https://www.dovepress.com/safety-and-tolerability-of-bilastine-06-ophthalmic-solution-an-8-weeks-peer-reviewed-fulltext-article-OPTH

Efficacy, Safety and Immunogenicity of AVT02 Versus Originator Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis:A Multicentre, Double-Blind, Randomised, Parallel Group, Active Control, Phase III Study

Autor: Hendrik Otto, Grazyna Pulka, Külli Kingo, Roshan Dias, Fausto Berti, Richard Kay, Halimu N. Haliduola, Nataliya Reznichenko, Eric Guenzi, George Galdava, Steven R. Feldman, Joanna Sobierska, Heimo Stroissnig

Publikováno v: Feldman, S R, Reznichenko, N, Pulka, G, Kingo, K, George Galdava, Berti, F, Sobierska, J, Dias, R, Guenzi, E, Hendrik Otto, Haliduola, H N, Kay, R & Stroissnig, H 2021, ' Efficacy, Safety and Immunogenicity of AVT02 Versus Originator Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis : A Multicentre, Double-Blind, Randomised, Parallel Group, Active Control, Phase III Study ', BioDrugs, vol. 35, no. 6, pp. 735-748 . https://doi.org/10.1007/s40259-021-00502-w
Biodrugs

Background AVT02 (adalimumab) is a proposed biosimilar to Humira®. AVT02 is produced at a 100 mg/mL concentration with a citrate-free formulation. Objectives The aim of this study was to compare the efficacy, safety and immunogenicity of AVT02 versu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9abf66f1bee2ff164778cbe7acdd210a
https://findresearcher.sdu.dk:8443/ws/files/195534959/Feldman2021_Article_EfficacySafetyAndImmunogenicit.pdf

Prothrombotic State in Asthma Is Related to Increased Levels of Inflammatory Cytokines, IL-6 and TNFα, in Peripheral Blood

Autor: Lech Zareba, Anetta Undas, Teresa Iwaniec, Lucyna Mastalerz, Romy Kremers, Michal Zabczyk, Agnieszka Cybulska, Grazyna Pulka, Stanisława Bazan-Socha, Coenraad Hemker

Publikováno v: Inflammation
Inflammation, 40(4), 1225-1235. Springer

Recently, we have reported that asthma is associated with enhanced plasma thrombin formation and impaired fibrinolysis. The mechanisms underlying the prothrombotic state in this disease are unknown. Our aim was to investigate whether prothrombotic al

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::93e92d56b3174e55712e431efdba785d
http://europepmc.org/articles/PMC5494034

Asthma is associated with enhanced thrombin formation and impaired fibrinolysis

Autor: Lech Zareba, Anetta Undas, Lucyna Mastalerz, Coenraad Hemker, Agnieszka Cybulska, Grazyna Pulka, Teresa Iwaniec, Michal Zabczyk, Stanisława Bazan-Socha, Romy Kremers

Publikováno v: Clinical and Experimental Allergy, 46(7), 932-944. Wiley-Blackwell

Background There is evidence that altered blood coagulation and fibrinolysis are involved in the pathogenesis of asthma. Increased thromboembolic risk has been reported in asthmatics. Objective To investigate whether enhanced thrombin generation and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::638e974e3bcd2f93736f9c06d08e54e7
https://doi.org/10.1111/cea.12734